ICON Acquisition Creates World-Leading Healthcare Intelligence and Clinical Research Organisation

ICON plc, announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees across 47 countries, creating the world’s most advanced healthcare intelligence and clinical research organisation.

Recommended AI News: Identity Verification Platform Sumsub Raises $6 Million in Series a From MetaQuotes

The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customers’ commercial success through the development of much needed medicines and medical devices. The new ICON will have a renewed focus on leveraging data, applying technology and accessing diverse patient populations to speed up drug development.

Recommended AI News: Identity Verification Platform Sumsub Raises $6 Million in Series a From MetaQuotes

Transaction close details

Upon completion of the acquisition, pursuant to the terms of the merger agreement, PRA became a wholly owned subsidiary of ICON plc. Under the terms of the merger, PRA shareholders received per share $80 in cash and 0.4125 shares of ICON stock. The trading of PRA common stock on NASDAQ was suspended prior to market open on July 1, 2021.

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives.

Recommended AI News: PRophet Announces Exclusive Partnership With Podchaser, Using AI To Pitch Podcast Creators